Goldfinch Bio, Inc.
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2015-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
5
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases
- Conditions
- NephritisNephrosisFocal Segmental NephrosisGlomerulonephritisKidney DiseasesGlomerulosclerosisLipoid Urologic Disease
- Interventions
- First Posted Date
- 2021-07-06
- Last Posted Date
- 2022-11-15
- Lead Sponsor
- Goldfinch Bio, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT04950114
- Locations
- 🇺🇸
Academic Medical Research Institute (AMRI), Los Angeles, California, United States
🇺🇸Amicis Research Center, Northridge, California, United States
🇺🇸Kidney and Hypertension Center - Apple Valley, Victorville, California, United States
First-In-Human Study of GFB-024 in Healthy Overweight and Obese Participants, and Participants With Type 2 Diabetes
- Conditions
- Diabetes MellitusKidney DiseasesDiabetes ComplicationsDiabetic NephropathiesEndocrine System Diseases
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-05-10
- Last Posted Date
- 2022-03-28
- Lead Sponsor
- Goldfinch Bio, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT04880291
- Locations
- 🇺🇸
Worldwide Clinical Trials, San Antonio, Texas, United States
A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease
- Conditions
- Diabetes ComplicationsGlomerulonephritisKidney DiseasesGlomerulosclerosis, Focal SegmentalNephrosis, LipoidUrologic DiseasesNephrosisDiabetic NephropathiesDiabetes MellitusEndocrine System Diseases
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-05-13
- Last Posted Date
- 2022-11-15
- Lead Sponsor
- Goldfinch Bio, Inc.
- Target Recruit Count
- 96
- Registration Number
- NCT04387448
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Aventiv Research - Phoenix, Mesa, Arizona, United States
🇺🇸Arizona Kidney Disease & Hypertension Centers (AKDHC), Scottsdale, Arizona, United States
A Study to Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN)
- Conditions
- Glomerulosclerosis, Focal SegmentalDiabetic NephropathiesMinimal Change Disease
- First Posted Date
- 2020-01-22
- Last Posted Date
- 2021-07-20
- Lead Sponsor
- Goldfinch Bio, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT04235621
- Locations
- 🇺🇸
Aventiv Research - Phoenix, Mesa, Arizona, United States
🇺🇸Glendale Adventist Medical Center, Glendale, California, United States
🇺🇸DaVita Mojave Sage Dialysis, Victorville, California, United States
FIH Ph 1 Study of TRPC5 Channel Inhibitor GFB-887 in Healthy Subjects
- First Posted Date
- 2019-05-31
- Last Posted Date
- 2020-06-02
- Lead Sponsor
- Goldfinch Bio, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT03970122
- Locations
- 🇺🇸
Covance Clinical Research Unit Inc., Dallas, Texas, United States